ArticleJournal of immunology (Baltimore, Md. : 1950)2020
Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma.
Article in Journal of immunology (Baltimore, Md. : 1950), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 44 citations in OpenAlex.
- Liposomes in tumor treatment: a double-edged sword.Science China. Life sciences · 2026Review
- Article
- Combining spatial and single-cell transcriptome data to analyze tertiary lymphoid structures in clear cell renal cell carcinoma reveals prognostic biomarkers.Journal of translational medicine · 2026Article
- Tumor-associated neutrophils in renal cell carcinoma.Frontiers in immunology · 2026Review
- Identification of C1QA as a prognostic marker and regulator of immunosuppressive neutrophils in early-stage lung adenocarcinoma through integrated bioinformatics analyses.Clinical and experimental medicine · 2025Article
- Urine C-reactive protein content and non-invasive molecular grading of renal cell carcinoma.Kidney cancer journal : official journal of the Kidney Cancer Association · 2025Article
- Enigmatic Roles of Complement Anaphylatoxin Signaling in Health and Disease.Immune network · 2025Review
- A prognostic microRNA-based signature for localized clear cell renal cell carcinoma: the Bio-miR study.British journal of cancer · 2025Article
- GFOD1 expression in clear cell renal cell carcinoma and its role in cancer cell proliferation, migration, and invasion.Discover oncology · 2025Article
- The complement system and kidney cancer: pathogenesis to clinical applications.The Journal of clinical investigation · 2025Review
- Targeting the complement system: notes on therapeutic strategies for renal cancer.Future medicinal chemistry · 2025Article
- Complement C3 of tumor-derived extracellular vesicles promotes metastasis of RCC via recruitment of immunosuppressive myeloid cells.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Host and bacterial urine proteomics might predict treatment outcomes for immunotherapy in advanced non-small cell lung cancer patients.Frontiers in immunology · 2025Article
- Hypoxia-induced complement component 3 promotes aggressive tumor growth in the glioblastoma microenvironment.JCI insight · 2024Article
- Analysis ofHeliyon · 2024Article
- Review
- Plasma proteome fingerprint in kidney diseases.Frontiers in molecular biosciences · 2024Article
- Humoral complementomics - exploration of noninvasive complement biomarkers as predictors of renal cancer progression.Oncoimmunology · 2024Article
- Identification and Validation of Cytotoxicity-Related Features to Predict Prognostic and Immunotherapy Response in Patients with Clear Cell Renal Cell Carcinoma.Genetics research · 2024Article
- Complement System and the Kidney: Its Role in Renal Diseases, Kidney Transplantation and Renal Cell Carcinoma.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
Abstract
Preclinical studies demonstrated that complement promotes tumor growth. Therefore, we sought to determine the best target for complement-based therapy among common human malignancies. High expression of 11 complement genes was linked to unfavorable prognosis in renal cell carcinoma. Complement protein expression or deposition was observed mainly in stroma, leukocytes, and tumor vasculature, corresponding to a role of complement in regulating the tumor microenvironment. Complement abundance in tumors correlated with a high nuclear grade. Complement genes clustered within an aggressive inflammatory subtype of renal cancer characterized by poor prognosis, markers of T cell dysfunction, and alternatively activated macrophages. Plasma levels of complement proteins correlated with response to immune checkpoint inhibitors. Corroborating human data, complement deficiencies and blockade reduced tumor growth by enhancing antitumor immunity and seemingly reducing angiogenesis in a mouse model of kidney cancer resistant to PD-1 blockade. Overall, this study implicates complement in the immune landscape of renal cell carcinoma, and notwithstanding cohort size and preclinical model limitations, the data suggest that tumors resistant to immune checkpoint inhibitors might be suitable targets for complement-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.